The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: A Taiwanese population-based nested case-control study

Diabetologia

Volumn 53, Issue 3, 2010, Pages 489-496

  Hsiao, F Y ^a   Mullins, C D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Case control study; Fracture; Thiazolidinediones; Type 2 diabetes mellitus; TZDs

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; FEMALE; FEMUR FRACTURE; FRACTURE; HIP FRACTURE; HOSPITALIZATION; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION; VERTEBRA FRACTURE; WRIST FRACTURE; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; DIABETES MELLITUS; FRACTURES, BONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; TAIWAN;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TAIWAN; THIAZOLIDINEDIONES;

EID: 77949261502     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1609-z     Document Type: Article

References (21)

1. NB Watts DA D'Alessio 2006 Type 2 diabetes, thiazolidinediones: bad to the bone? J Clin Endocrinol Metab 91 3276 3278 10.1210/jc.2006-1235 1:CAS:528:DC%2BD28Xpslajsbg%3D 16960122 (Pubitemid 44402089)
2. AV Schwartz DE Sellmeyer 2007 Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 30 1670 1671 10.2337/dc07-0554 1:CAS:528:DC%2BD2sXntlWktbk%3D 17526825 (Pubitemid 46871197)
3. SO Rzonca LJ Suva D Gaddy DC Montague B Lecka-Czernik 2004 Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 145 401 406 10.1210/en.2003-0746 1:CAS:528:DC%2BD3sXhtVWgtL7O 14500573 (Pubitemid 38094536)
4. OP Lazarenko SO Rzonca WR Hogue FL Swain LJ Suva B Lecka-Czernik 2007 Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone Endocrinology 148 2669 2680 10.1210/en.2006-1587 1:CAS:528:DC%2BD2sXmt1ajt70%3D 17332064 (Pubitemid 46984815)
5. V Sottile K Seuwen M Kneissel 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone) Calcif Tissue Int 75 329 337 10.1007/s00223-004-0224-8 1:CAS:528:DC%2BD2cXpsl2isLk%3D 15549648 (Pubitemid 40064235)
6. MA Sorocéanu D Miao XY Bai H Su D Goltzman AC Karaplis 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J Endocrinol 183 203 216 10.1677/joe.1.05723 15525588 (Pubitemid 40124657)
7. AA Ali RS Weinstein SA Stewart AM Parfitt SC Manolagas RL Jilka 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 1226 1235 10.1210/en.2004-0735 1:CAS:528:DC%2BD2MXitlehtro%3D 15591153 (Pubitemid 40289310)
8. AV Schwartz DE Sellmeyer E Vittinghoff, et al. 2006 Thiazolidinedione use and bone loss in older diabetic adults J Clin Endocrinol Metab 91 3349 3354 10.1210/jc.2005-2226 1:CAS:528:DC%2BD28Xpslajt74%3D 16608888 (Pubitemid 44402103)
9. A Grey M Bolland G Gamble, et al. 2007 The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 92 1305 1310 10.1210/jc.2006-2646 1:CAS:528:DC%2BD2sXksVSrtr4%3D 17264176 (Pubitemid 46556402)
10. S Yaturu B Bryant SK Jain 2007 Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men Diabetes Care 30 1574 1576 10.2337/dc06-2606 1:CAS:528:DC%2BD2sXntlWkt7o%3D 17363747 (Pubitemid 46876524)
11. SE Kahn SM Haffner MA Heise ADOPT Study Group, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF 17145742 (Pubitemid 44903747)
12. SE Kahn B Zinman JM Lachin Diabetes Outcome Progression Trial (ADOPT) Study Group, et al. 2008 Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 845 851 10.2337/dc07-2270 1:CAS:528:DC%2BD1cXmsFGrt7o%3D 18223031
13. C Meier ME Kraenzlin M Bodmer SS Jick H Jick CR Meier 2008 Use of thiazolidinediones and fracture risk Arch Intern Med 168 820 825 10.1001/archinte.168.8.820 1:CAS:528:DC%2BD1cXmtFSrsLg%3D 18443256 (Pubitemid 351620084)
14. E Barrett-Connor ES Siris LE Wehren, et al. 2005 Osteoporosis and fracture risk in women of different ethnic groups J Bone Miner Res 20 185 194 10.1359/JBMR.041007 15647811
15. Bureau of National Health Insurance (2007) National Health Insurance in Taiwan. Available at www.nhi.gov.tw/english/index.asp, accessed 20 August 2009
16. M Monami B Cresci A Colombini, et al. 2008 Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study Diabetes Care 31 199 203 10.2337/dc07-1736 18024851 (Pubitemid 351213319)
17. YK Loke S Singh CD Furberg 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ 180 32 39 19073651
18. T Hampton 2007 Diabetes drugs tied to fractures in women JAMA 297 1645 10.1001/jama.297.15.1645 1:CAS:528:DC%2BD2sXksVGqsrw%3D 17440138 (Pubitemid 46631642)
19. GlaxoSmithKline (GSK) (2007) Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus (Letter to Health Care Providers). Available at www.fda.gov/MedWatch/safety/2007/Avandia- GSK-Ltr.pdf, accessed 20 March 2009
20. Takeda (2007) Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus (Letter to Health Care Providers). Available at www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf, accessed 20 March 2009
21. R Short 2007 Fracture risk is a class effect of glitazones BMJ 334 551 10.1136/bmj.39154.373889.DB 17363794